Here come the drugs

April 2004
U.S. Catholic;Apr2004, Vol. 69 Issue 4, p10
Reports on the free antiretroviral drugs given by the Catholic Church to South Africans infected with HIV and AIDS. Number of South Africans infected; Plan for the church-run projects for the drugs; Statement from Bishop Kevin Dowling about the proposed antiretroviral drug program from the South African government.


Related Articles

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

  • Review of antiretroviral agents for the treatment of HIV infection. Stanic, Anela; Grana, Julie C. // Formulary;Feb2009, Vol. 44 Issue 2, p47 

    Research into the treatment of HIV infection has resulted in the development of 5 antiretroviral (ARV) drug classes: entry inhibitors, including fusion inhibitors and chemokine coreceptor (CCR) inhibitors; nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse...

  • Tenofovir and Nephrotoxicity. Joshi, Amit; Kraus, Mark // Kidney;Nov/Dec2005, Vol. 14 Issue 6, p255 

    The article provides information on the development of antiretroviral drug tenofovir for the treatment of HIV/AIDS. Tenofovir is an acyclic nucleoside phosphonate in the class of nucleotide reverse transcriptase inhibitors. The drug interrupts DNA synthesis by terminating the elongation of the...

  • ART adherence adequate in Africa although still a global concern.  // PharmacoEconomics & Outcomes News;8/26/2006, Issue 510, p3 

    The article presents information on a meta-analysis of studies that examined levels of adherence to antiretroviral therapy in patients with HIV infection. The analysis revealed that patients in the African studies demonstrated a significantly greater level of adherence than those in the North...

  • Tipranavir. Flexner, Charles; Bate, Guy; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Dec2005, Vol. 4 Issue 12, p955 

    The article focuses on the discovery of Tipranavir, a drug used in the treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents. The development of antiretroviral regimens in which inhibitors of the HIV-1 protease are combined with nucleoside...

  • No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. Winzer, Ralf; Langmann, Peter; Zilly, Michael; Tollmann, Franz; Schubert, Jörg; Klinker, Hartwig; Weissbrich, Benedikt // Annals of Clinical Microbiology & Antimicrobials;2005, Vol. 4, p3 

    Background: In a retrospective study of HIV-infected patients, we investigated the influence of the MDR1 genotype (G2677T/A and C3435T) on the virological and immunological response of treatment naïve patients. Methods: The MDR1 genotype was analysed from 72 patients in whom antiretroviral...

  • HIV-Associated Lipoatrophy What Are the Kinder, Gentler Agents? Dubé, Michael P. // Clinical Infectious Diseases;1/15/2006, Vol. 42 Issue 2, p281 

    The article informs that lipoatrophy associated with antiretroviral treatment of HIV infection is a serious problem that is associated with significant aesthetic and metabolic derangements. Therapy with thiazolidenediones or switching of therapy to nucleoside reverse-transcriptase inhibitors is...

  • Poly-L-Lactic Acid: A Viewpoint by Christine Katlama. Katlama, Christine // American Journal of Clinical Dermatology;2004, Vol. 5 Issue 5, p367 

    Presents a commentary about poly-L-lactic acid. Association of lipodystrophy with highly active antiretroviral therapy; Treatment option for facial lipoatrophy; Application of poly-L-lactic acid in the treatment of HIV-related atrophy.

  • Antiretrovirals.  // Reactions Weekly;12/1/2007, Issue 1180, p4 

    The article presents a medical case of a 45-year-old man who developed oral lipomatosis while receiving an antiretroviral regimen. The regimen comprises stavudine, didanosine, indinavir and ritonavir for the treatment of HIV infection. It was relatively tolerated but after 6 months of treatment,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics